MDL | MFCD00012904 |
---|---|
Molecular Weight | 113.61 |
Molecular Formula | C2H8ClNS |
SMILES | SCCN.Cl |
Cysteamine hydrochloride (2-Aminoethanethiol hydrochloride) is an orally active agent for the treatment of nephropathic cystinosis and an antioxidant.
Human Endogenous Metabolite |
Cysteamine hydrochloride (2-Aminoethanethiol hydrochloride) has been shown to increase intracellular glutathione levels in cystinotic cells, thus restoring the altered redox state of the cells. Also increased rates of apoptosis in cystinotic cells, which are thought to be the result of increased caspase 3 and protein kinase Cε activity, is counteracted by Cysteamine hydrochloride administration. Cysteamine hydrochloride has antioxidant properties as a result of increasing glutathione production. Cysteamine hydrochloride is an excellent scavenger of OH and HOCl; it also reacts with H2O2. Cysteamine hydrochloride increases the production of several heat shock proteins (HSP), including the murine Hsp40. Cysteamine hydrochloride exerts a dose-dependent effect on the doxorubicin-induced death of cancer cells, measured in both HeLa cells and B16 cells, whereas Cysteamine hydrochloride treatment alone had no influence on cell survival. In addition, in a doxorubicin-resistant breast cancer cell line, the addition of Cysteamine hydrochloride to doxorubicin results in a dramatic increase in cell death
[1]
.
Cysteamine hydrochloride (100 μM) significantly is able to increase the intracellular GSH levels and the percentage of embryos that developed to the blastocyst stage of culture matured oocytes
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT02766855 | The Eye Center and The Eye Foundation for Research in Ophthalmology |
Nephropathic Cyctinosis|Corneal Cystine Crystals
|
January 2004 | Not Applicable |
NCT01000961 | Horizon Pharma USA, Inc. |
Cystinosis
|
June 2010 | Phase 3 |
NCT00715559 | Icahn School of Medicine at Mount Sinai |
Major Depressive Disorder
|
July 2008 | Not Applicable |
NCT02735707 | UMC Utrecht|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|Intensive Care National Audit & Research Centre|St. Marianna University School of Medicine|National Intensive Care Surveillance MORU |
Community-acquired Pneumonia, Influenza, COVID-19
|
April 11, 2016 | Phase 3 |
NCT01139125 | Augusta University |
Schizophrenia|Schizoaffective
|
September 2009 | Not Applicable |
NCT01529268 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Advancing Translational Sciences (NCATS)|National Cancer Institute (NCI)|Raptor Pharmaceuticals |
Nonalcoholic Fatty Liver Disease (NAFLD)
|
June 2012 | Phase 2|Phase 3 |
NCT04246060 | Chiesi SA+NV |
Nephropathic Cystinosis
|
July 31, 2020 | |
NCT00799578 | Joel Lavine|Raptor Pharmaceuticals Corp.|University of California, San Diego |
Fatty Liver
|
October 2008 | Phase 1|Phase 2 |
NCT01197378 | Horizon Pharma USA, Inc. |
Cystinosis
|
August 27, 2010 | Phase 3 |
NCT00010426 | FDA Office of Orphan Products Development|Leadiant Biosciences, Inc. |
Cystinosis
|
December 1999 | Not Applicable |
NCT02473445 | Horizon Pharma USA, Inc. |
Mitochondrial Diseases
|
May 19, 2015 | Phase 2 |
NCT02023866 | Horizon Pharma USA, Inc. |
Inherited Mitochondrial Disease, Including Leigh Syndrome
|
May 2014 | Phase 2 |
NCT02012114 | Hospices Civils de Lyon |
Cystinosis
|
December 2011 | Not Applicable |
NCT01432561 | University of California, San Diego|Raptor Pharmaceuticals Corp. |
Cystinosis|Nephropathic Cystinosis
|
September 2011 | Not Applicable |
NCT00001736 | National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC) |
Cystinosis
|
May 1998 | Phase 1 |
NCT00002110 | Mylan Laboratories|NIH AIDS Clinical Trials Information Service |
HIV Infections
|
Phase 2 | |
NCT05206318 | Chang Gung Memorial Hospital|Scientis Pharma SA |
Hyperpigmentation; Postinflammatory
|
December 10, 2021 | Not Applicable |
NCT02212431 | University of Aberdeen|Cystic Fibrosis Trust|NHS Grampian|University of Huddersfield |
Cystic Fibrosis
|
August 2014 | Phase 1|Phase 2 |
NCT03883984 | Children´s Hospital Medical Center, Cincinnati |
Asthma
|
June 18, 2019 | Phase 1 |
NCT03000348 | NovaBiotics Ltd.|Agility Clinical, Inc.|PSR Group B.V. |
Cystic Fibrosis
|
December 2016 | Phase 2 |
NCT00001213 | National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC) |
Cystinosis
|
April 1986 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
DMSO : 100 mg/mL ( 880.20 mM ; Need ultrasonic)
H 2 O : ≥ 50 mg/mL ( 440.10 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 8.8020 mL | 44.0102 mL | 88.0204 mL |
5 mM | 1.7604 mL | 8.8020 mL | 17.6041 mL |
10 mM | 0.8802 mL | 4.4010 mL | 8.8020 mL |
Add each solvent one by one: PBS
Solubility: 100 mg/mL (880.20 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (18.31 mM); Clear solution
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (18.31 mM); Clear solution